New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2012
10:20 EDTSYNC, NCMI, TNB, SIGA, MAKO, SNCR, RHHBY, EA, EP, BP, ERJ, ACMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AECOM Technology (ACM) downgraded to Underperform from Buy at BofA/Merrill... BP (BP) downgraded to Underweight from Equal Weight at Barclays... El Paso (EP) downgraded to Underweight from Neutral at Atlantic Equities... Embraer (ERJ) downgraded to Neutral from Buy at Citigroup... Mako Surgical (MAKO) downgraded to Neutral from Buy at Mizuho... National CineMedia (NCMI) downgraded to In-Line from Outperform at Imperial Capital... Roche (RHHBY) downgraded to Neutral from Overweight at JPMorgan... SIGA Technologies (SIGA) downgraded to Sector Perform from Outperform at RBC Capital... Synacor (SYNC) downgraded to Underperform from Buy at BofA/Merrill... Synchronoss (SNCR) downgraded to Market Perform from Outperform at Wells Fargo... Thomas & Betts (TNB) downgraded to Neutral from Outperform at RW Baird... Electronic Arts (EA) downgraded to Market Perform from Outperform at William Blair.
News For ACM;BP;EP;ERJ;MAKO;NCMI;RHHBY;SIGA;SYNC;SNCR;TNB;EA From The Last 14 Days
Check below for free stories on ACM;BP;EP;ERJ;MAKO;NCMI;RHHBY;SIGA;SYNC;SNCR;TNB;EA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 15, 2014
09:59 EDTERJEmbraer reports 34 jet deliveries in Q1
During the first quarter of 2014, Embraer delivered 14 jets to the commercial aviation market and 20 to the business aviation market, for a total of 34 aircraft, compared to 29 aircraft delivered in the same period of 2013. On March 31, the firm order backlog totaled $19.2B, an increase of $1B over December 31, 2013.
09:02 EDTRHHBYRoche confirms FY outlook for low-to mid-single digit growth in sales
Subscribe for More Information
09:01 EDTRHHBYRoche reports Q1 sales CHF11.496B vs. CHF11.589B a year ago
Roche reported Q1 group sales rose 5% at constant exchange rates and fell 1% in Swiss francs compared to the prior year. Pharma sales were up 4%, with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for expected decline in Xeloda sales, while Diagnostics division sales were up 7%. Roche CEO Severin Schwan said: “Both the Pharma and Diagnostics Divisions posted solid growth in the first quarter. I am particularly pleased with the strong uptake of our recently launched medicines Perjeta and Kadcyla for HER2-positive breast cancer."
08:23 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTRHHBYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
10:02 EDTBPOn The Fly: Analyst Upgrade Summary
Acorda Therapeutics (ACOR) upgraded to Outperform from Market Perform at FBR Capital... Allegheny Technologies (ATI) upgraded to Neutral from Underperform at Sterne Agee... BP (BP) upgraded to Buy from Hold at Canaccord... Bloomin' Brands (BLMN) upgraded to Buy from Hold at Deutsche Bank... Boardwalk Pipeline (BWP) upgraded to Neutral from Underperform at BofA/Merrill... Boston Scientific (BSX) upgraded at BofA/Merrill... Charles Schwab (SCHW) upgraded to Buy from Neutral at UBS... Citigroup (C) upgraded to Hold from Sell at Rafferty Capital... Community Health (CYH) upgraded to Outperform from Perform at Oppenheimer... Eaton Vance (EV) upgraded to Neutral from Sell at Citigroup... Eli Lilly (LLY) upgraded to Hold from Underperform at Jefferies... F5 Networks (FFIV) upgraded to Buy from Hold at Stifel... HeartWare (HTWR) upgraded to Buy from Neutral at BTIG... Heartland Payment (HPY) upgraded to Hold from Sell at Stifel... Hyatt Hotels (H) upgraded to Outperform from Market Perform at FBR Capital... MasterCard (MA) upgraded to Outperform from Neutral at RW Baird... McDermott (MDR) upgraded to Neutral from Underweight at HSBC... Palo Alto (PANW) upgraded to Overweight at Stephens... PetroChina (PTR) upgraded to Neutral from Underperform at Credit Suisse... Seagate (STX) upgraded to Buy from Hold at Argus... Sensata (ST) upgraded to Buy from Neutral at Citigroup... Stryker (SYK) upgraded to Neutral from Reduce at SunTrust... TD Ameritrade (AMTD) upgraded to Buy from Neutral at UBS... TTM Technologies (TTMI) upgraded to Buy from Hold at Stifel... Transocean (RIG) upgraded to Hold from Sell at Deutsche Bank... VMware (VMW) upgraded to Outperform from Underperform at CLSA... Visa (V) upgraded to Outperform from Neutral at RW Baird... Yahoo (YHOO) upgraded to Buy from Neutral at SunTrust... Zimmer (ZMH) upgraded to Neutral from Reduce at SunTrust... bebe stores (BEBE) upgraded to Buy from Neutral at Janney Capital.
05:54 EDTBPBP upgraded to Buy from Hold at Canaccord
Subscribe for More Information
April 11, 2014
12:42 EDTACMOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:15 EDTEAElectronic Arts price target raised to $35 from $32 at Cowen
Cowen raised its price target on Electronic Arts citing the continuation of the console cycle, improved visibility on new titles, and the entrance into strong seasonality. Shares are Outperform rated.
08:11 EDTBPBP says can help improve relations between west, Russia, Reuters says
In an effort to calm shareholders' worries over the company's large exposure to Russia, BP executives said it can help improve relations between Russia and the west and is talking to politicians all over the globe, according to Reuters, citing comments from CEO Bob Dudley. Reference Link
07:55 EDTACMAECOM Technology downgraded to Neutral from Buy at DA Davidson
DA Davidson downgraded AECOM Technology due to valuation. Price target is $35.
April 10, 2014
11:42 EDTRHHBYReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
April 8, 2014
16:10 EDTRHHBYProthena says first human dosed in Phase 1 study of PRX002
Prothena (PRTA) announced the successful start of a Phase 1 clinical trial of its therapeutic monoclonal antibody candidate, PRX002, for the treatment of Parkinson's disease. Prothena has earned a $15M milestone payment from Roche (RHHBY) related to the initiation of this study. The initial Phase 1 clinical trial of PRX002 is a randomized, double-blind, placebo-controlled, single ascending dose study in healthy subjects. It is designed to assess PRX002 for safety, tolerability, pharmacokinetics and immunogenicity. As previously announced in December 2013, Prothena entered into a worldwide collaboration with Roche to develop and commercialize antibodies that target α-synuclein, including PRX002. Including the current milestone payment, Prothena has now achieved a total of $45M through its worldwide PRX002 collaboration with Roche.
11:03 EDTRHHBYPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.
April 7, 2014
06:07 EDTRHHBYRoche acquires IQuum for $450M
Subscribe for More Information
April 4, 2014
06:24 EDTEAElectronic Arts hires Sony developer Amy Hennig
Subscribe for More Information
April 3, 2014
10:03 EDTRHHBYRoche unit signs companion diagnostic agreement with Genmab
Ventana Medical Systems, a member of the Roche Group, announced that it has entered into an agreement with Genmab A/S for the development of companion diagnostic tools for Genmab's HuMax-TF-ADC antibody drug conjugate program. The TF assay will be developed for possible designation as the screening test in clinical trials involving HuMax-TF-ADC.
10:00 EDTBPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:43 EDTBPBP initiated with a Market Perform at BMO Capital
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use